Corline Biomedical

Corline Biomedical, founded in 2005 and based in Uppsala, Sweden, has developed the Corline Heparin Conjugate (CHC™), a unique macromolecular technology that mimics the natural blood-compatible lining of blood vessels. The company operates a dual business model, generating revenue by supplying its CHS™ coating to medical device partners while advancing its proprietary pipeline, Renaparin® and Cytoparin™, in high-value regenerative medicine fields like kidney transplantation and cell therapy. Listed on Nasdaq First North (CORLINE), Corline leverages a strong scientific foundation of over 100 publications to drive innovation and partnerships in areas of significant unmet clinical need.

The Corline Heparin Conjugate (CHC™) is a proprietary macromolecular technology consisting of pre-assembled aggregates of heparin molecules, designed to mimic the natural heparan sulfate proteoglycans on blood vessel walls, providing dense, stable, and highly bioactive antithrombotic and anti-inflammatory surfaces.

Corline competes with large chemical suppliers offering passive coatings and other active heparin technologies in the device space, differentiating through its superior macromolecular CHC™ platform. In regenerative medicine, its localized, biomimetic approach to preventing inflammation and rejection is unique compared to systemic drugs or novel biologics.